8-K: Rezolute Upbeat on Ersodetug Phase 3 Study Interim Data

Rezolute, Inc. announced positive interim data from its Phase 3 upLIFT study of ersodetug for tumor hyperinsulinism, with 6 of 8 participants meeting the primary endpoint.

Summary

• Rezolute, Inc. provided an interim update on its Phase 3 upLIFT study for ersodetug in tumor hyperinsulinism (HI).
• The study is 50% enrolled with 8 out of 16 planned participants.
• Six of the eight enrolled participants have already met the primary endpoint, achieving at least a 50% reduction in intravenous glucose requirements.
• These six participants also achieved complete discontinuation of intravenous glucose.
• One participant withdrew consent and is counted as a non-responder due to their advanced cancer and transition to hospice care.
• The eighth participant is still in the pivotal treatment phase.
• All participants who completed the 8-week pivotal treatment have opted to continue into the open-label extension.
• Ersodetug has been well-tolerated with no drug-related adverse events reported.
• Topline results for the fully enrolled study are expected in the second half of 2026.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a highly positive update due to the strong interim efficacy and safety data, exceeding expectations for the study's primary endpoint.

Positives

• 6 out of 8 enrolled participants met the primary endpoint of at least a 50% reduction in intravenous glucose requirements.
• These 6 participants also achieved complete discontinuation of intravenous glucose.
• The interim data largely mirrors previously observed results from an expanded access program.
• Ersodetug has demonstrated clinically impactful hypoglycemia-correcting activity.
• The drug has been well-tolerated with no drug-related adverse events or safety findings reported to date.
• All participants completing the pivotal phase have elected to continue into the open-label extension.

Negatives

• One participant withdrew consent and is counted as a non-responder due to advanced cancer (Stage 4 metastatic colon cancer, ECOG 4) and transition to hospice care.
• The study is still midway through enrollment, with topline results not expected until the second half of 2026.

Risks

• Actual results may differ materially from anticipated results due to inherent uncertainties in predicting results or the actual effects of plans or strategies.
• Important factors that may cause differences include those discussed in the Company's SEC filings, including Risk Factors in its Form 10-K and 10-Q.
• The Company cautions against undue reliance on forward-looking statements.

Future Outlook

Topline results for the fully enrolled upLIFT study are expected in the second half of 2026. The company continues to engage with the FDA to determine the path forward for the congenital HI indication.

Management Comments

• "We are very excited by the interim observations from the upLIFT study as they largely mirror what we previously observed and reported from an initial case series of patients from our expanded access program for compassionate use."
• "These results reveal the clinically impactful hypoglycemia-correcting activity of ersodetug in an unbiased GIR assessment in patients with HI caused by varying tumor types."
• "This further highlights the aberrant outcome from the recently completed randomized, placebo-controlled, Phase 3 sunRIZE study in pediatric congenital HI, where we believe that self-monitored glycemic measures were confounded by divergent caretaker behaviors stemming from functional unblinding to treatment status by real-time glucose monitoring."
• "Importantly, these findings continue to support the potential for ersodetug to be a universal treatment option for patients with serious and refractory hypoglycemia caused by congenital and a variety of acquired forms of hyperinsulinism, including tumor HI and following bariatric and non-bariatric gastrointestinal surgeries."
• "We look forward to announcing topline results of the fully enrolled upLIFT study in tumor HI in the second half of 2026, as well as continuing our engagement with FDA to determine the path forward for the congenital HI indication."

Industry Context

StockSavvy.ai notes that Rezolute's positive interim data for ersodetug in tumor hyperinsulinism, particularly the high responder rate and complete glucose discontinuation, is a significant development in the ultra-rare disease space. The company's commentary on the potential confounding factors in the prior sunRIZE study also suggests a strategic approach to navigating regulatory pathways for indications with complex monitoring requirements.

Stakeholder Impact

• Shareholders: Positive interim data may lead to increased investor confidence and potential stock price appreciation.
• Patients with Tumor Hyperinsulinism: Potential for a new, effective treatment option for a serious and refractory condition.
• Healthcare Providers: Provides further evidence for the efficacy and tolerability of ersodetug in treating complex hypoglycemia cases.

Next Steps

• Announce topline results of the fully enrolled upLIFT study in the second half of 2026.
• Continue engagement with the FDA to determine the path forward for the congenital HI indication.

Key Dates

Recommendation

The strong interim efficacy and safety data from the upLIFT study, with a high proportion of patients meeting the primary endpoint and achieving complete glucose discontinuation, coupled with good tolerability, suggests a high probability of success for ersodetug in tumor hyperinsulinism. This positive development, along with the company's strategic engagement with the FDA for other indications, warrants a strong buy recommendation.

Keywords

Rezolute, ersodetug, hyperinsulinism, tumor HI, Phase 3 study, upLIFT study, hypoglycemia, clinical trial